Protean to Present Advanced AI Research at AACR22

Protean BioDiagnostics develops AI approach to detect specific EGFR mutations in lung cancer specimens using analysis of digital pathology images and will present findings at the AACR meeting.

Anthony MaglioccoApril 8, 2022

Protean to Present Novel Research Findings on Colorectal Cancer at AACR22

Protean BioDiagnostics identifies key molecular differences in Colorectal cancer between men and women with implications for treatment and screening.

Anthony MaglioccoApril 4, 2022

Protean Presents on the Use of Image Analysis for the Risk Classification of Barrett’s Esophagus

Protean to present updates on the innovative use of digital pathology and image analysis for improved classification of the risk of malignant transformation of Barrett’s esophagus at USCAP.

Anthony MaglioccoMarch 22, 2022

Protean Named as a 2022 Startup to Watch

Protean is proud to be listed by The Business Journals’ Orlando Inno as one of the 10 Florida startups poised to “shake up the innovation ecosystem in 2022”.

Anthony MaglioccoFebruary 14, 2022

Protean Presents Data on Breast Cancer Disparities in African American Women at SABCS

Although progress is being made against breast cancer in general, it seems African American women are being left behind.

The study entitled Distinct and targetable molecular features of breast cancer in African American women” was aimed at determining if breast cancer occurring in African American women might have different molecular features.

Anthony MaglioccoDecember 9, 2021

Protean Presents on OncoSignal at SABCS 2021

Protean BioDiagnostics presents a new method to identify potential therapeutic targets in breast cancer.

The method called OncoSignal analysis utilizes mRNA transcriptional measurements to accurately calculate the pathway activity of seven key oncogenic signaling pathways.

Anthony MaglioccoDecember 8, 2021